Cann Group Limited (CNGGF)
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cann Group Limited (CNGGF) ist im Healthcare-Sektor taetig, zuletzt notiert bei $ mit einer Marktkapitalisierung von 0. Bewertet mit 39/100 (vorsichtig) bei Wachstumspotenzial, finanzieller Gesundheit und Momentum.
Zuletzt analysiert: 15. März 2026Cann Group Limited (CNGGF) Gesundheitswesen & Pipeline-Uebersicht
Cann Group Limited, an Australian medicinal cannabis company founded in 2014, cultivates, produces, and manufactures medicinal cannabis for domestic and overseas markets. With a focus on research and development, the company navigates the evolving regulatory landscape to expand its market presence and product offerings in the specialty drug sector.
Investmentthese
Cann Group Limited presents a speculative investment opportunity within the burgeoning medicinal cannabis market. The company's vertically integrated operations, encompassing cultivation, production, and manufacturing, position it to capitalize on the increasing global demand for medicinal cannabis. A key value driver is the expansion into overseas export markets, offering significant revenue growth potential. The company's P/E ratio of 0.40, while potentially misleading due to the volatile nature of the cannabis industry, warrants further investigation into the underlying profitability drivers. Upcoming regulatory changes in key international markets could serve as a catalyst for increased market access. Potential risks include intense competition, evolving regulatory landscapes, and the need for continued capital investment to scale operations.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Market capitalization of $0.00B indicates the company's current valuation in the market.
- A P/E ratio of 0.40 suggests the company is potentially undervalued, but requires further investigation due to the industry's volatility.
- Profit Margin of 130.3% indicates strong profitability, but should be analyzed in the context of revenue and cost structure.
- Gross Margin of -20.8% indicates that the cost of goods sold exceeds revenue, requiring attention to operational efficiency.
- Beta of 0.01 suggests the stock has very low volatility compared to the overall market.
Wettbewerber & Vergleichsunternehmen
Staerken
- Licensed to cultivate and research cannabis.
- Vertically integrated operations.
- Focus on medicinal cannabis.
- Established presence in the Australian market.
Schwaechen
- Limited financial resources.
- Dependence on regulatory approvals.
- Intense competition in the cannabis industry.
- Negative gross margin.
Katalysatoren
- Upcoming: Regulatory approvals for new medicinal cannabis products in key markets.
- Ongoing: Expansion of distribution network in Australia and overseas.
- Ongoing: Increasing patient awareness and acceptance of medicinal cannabis.
- Upcoming: Positive clinical trial results for cannabis-based therapies.
- Ongoing: Strategic partnerships with pharmaceutical companies and healthcare providers.
Risiken
- Potential: Changes in regulations regarding medicinal cannabis.
- Ongoing: Competition from larger cannabis companies.
- Potential: Fluctuations in cannabis prices.
- Potential: Adverse health effects associated with medicinal cannabis.
- Ongoing: Dependence on regulatory approvals for market access.
Wachstumschancen
- Expansion into new international markets represents a significant growth opportunity for Cann Group. As more countries legalize or expand access to medicinal cannabis, the company can leverage its production capabilities and regulatory expertise to enter these markets. The global medicinal cannabis market is projected to reach billions of dollars in the coming years, offering substantial revenue potential for Cann Group. Timeline: Ongoing, with market entry dependent on regulatory approvals.
- Development of new cannabis-based therapies and products can drive revenue growth and enhance Cann Group's competitive advantage. Investing in research and development to create innovative formulations and delivery methods can attract new patients and expand the company's product portfolio. The market for specialized cannabis products is growing rapidly, offering opportunities for Cann Group to capture market share. Timeline: Ongoing, with new product launches expected in the next 1-3 years.
- Strategic partnerships with pharmaceutical companies and healthcare providers can accelerate Cann Group's market penetration and distribution reach. Collaborating with established players in the healthcare industry can provide access to new markets, distribution channels, and clinical expertise. Such partnerships can also enhance the credibility and acceptance of Cann Group's products among healthcare professionals. Timeline: Ongoing, with potential partnerships to be announced in the next 12-18 months.
- Increasing production capacity and improving operational efficiency can enhance Cann Group's profitability and competitiveness. Investing in state-of-the-art cultivation and manufacturing facilities can reduce production costs, improve product quality, and increase output. Streamlining operations and optimizing resource allocation can further enhance the company's financial performance. Timeline: Ongoing, with capacity expansions planned over the next 2-3 years.
- Focusing on patient education and awareness can drive demand for Cann Group's products and build brand loyalty. Educating patients and healthcare professionals about the benefits of medicinal cannabis and the company's products can increase adoption and improve patient outcomes. Participating in industry conferences, conducting clinical trials, and publishing research findings can enhance the company's credibility and reputation. Timeline: Ongoing, with increased marketing and educational initiatives planned for the next year.
Chancen
- Expansion into new international markets.
- Development of innovative cannabis-based therapies.
- Strategic partnerships with pharmaceutical companies.
- Increasing patient awareness and acceptance of medicinal cannabis.
Risiken
- Evolving regulatory landscape.
- Competition from larger cannabis companies.
- Fluctuations in cannabis prices.
- Potential for adverse health effects.
Wettbewerbsvorteile
- Licenses to cultivate cannabis for medicinal and research purposes.
- Established production and manufacturing capabilities.
- Clinical evaluation and research expertise.
- Access to domestic and international markets.
Ueber CNGGF
Cann Group Limited, established in 2014 and headquartered in Port Melbourne, Australia, operates within the medicinal cannabis sector. The company's core activities encompass the entire value chain, from breeding and cultivation to the production, manufacturing, and clinical evaluation of medicinal cannabis products. These products are intended for sale and use within Australia, as well as for export to international markets. Cann Group holds licenses that permit it to conduct research and cultivate cannabis specifically for human medicinal and research purposes. Cann Group's strategic focus includes developing pharmaceutical-grade cannabis products and expanding its distribution network both domestically and internationally. The company aims to establish itself as a leading supplier of medicinal cannabis by adhering to stringent quality standards and regulatory requirements. Cann Group's activities support the growing demand for medicinal cannabis as an alternative treatment option for various medical conditions. The company's commitment to research and development enables it to innovate and introduce new cannabis-based therapies to the market, further solidifying its position in the healthcare industry.
Was das Unternehmen tut
- Cultivates cannabis for medicinal purposes.
- Produces medicinal cannabis products.
- Manufactures cannabis-based pharmaceuticals.
- Conducts clinical evaluations of medicinal cannabis.
- Supplies medicinal cannabis for sale in Australia.
- Exports medicinal cannabis to overseas markets.
- Licenses research and cultivation of cannabis.
Geschaeftsmodell
- Cultivation and production of medicinal cannabis.
- Manufacturing and distribution of cannabis-based products.
- Licensing of cannabis research and cultivation.
- Sales to domestic and international markets.
Branchenkontext
Cann Group Limited operates in the rapidly expanding medicinal cannabis industry, which is experiencing significant growth due to increasing acceptance and legalization in various countries. The market is characterized by intense competition, with numerous companies vying for market share. Key trends include the development of innovative cannabis-based therapies, the expansion of distribution channels, and the evolving regulatory landscape. Cann Group's success depends on its ability to differentiate itself through product quality, research and development, and strategic partnerships. Competitors such as AVTBF (Avanti Health Technologies Inc.), CLABF (CLS Holdings USA Inc.), CPIVF (Canopy Rivers Inc.), CTABF (Canna-Global Acquisition Corp), and LIFD (Leafly Holdings Inc.) are also vying for market share.
Wichtige Kunden
- Patients requiring medicinal cannabis for various conditions.
- Pharmacies and healthcare providers in Australia.
- International distributors and partners.
- Research institutions conducting cannabis studies.
Finanzdaten
Chart & Info
Cann Group Limited (CNGGF) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
-
Stocks That Hit 52-Week Lows On Tuesday
· 24. März 2020
-
Stocks That Hit 52-Week Lows On Tuesday
· 26. Nov. 2019
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer CNGGF.
Kursziele
Wall-Street-Kurszielanalyse fuer CNGGF.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von CNGGF auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Fuehrung: Jennifer Lee Pilcher
CEO
Jennifer Lee Pilcher is the Chief Executive Officer of Cann Group Limited. Her background includes experience in the pharmaceutical and healthcare industries, with a focus on strategic leadership and business development. She has held various leadership roles in companies focused on commercializing healthcare products and expanding market access. Her expertise spans across regulatory affairs, product development, and commercial operations, making her well-suited to lead Cann Group in the evolving medicinal cannabis market.
Erfolgsbilanz: Under Jennifer Lee Pilcher's leadership, Cann Group has focused on expanding its production capabilities and pursuing strategic partnerships to enhance its market presence. She has overseen the company's efforts to navigate the complex regulatory landscape and secure necessary approvals for its products. Key milestones under her tenure include expanding into new international markets and developing innovative cannabis-based therapies.
CNGGF OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the OTC market, indicating that Cann Group Limited may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited information available to investors, potentially increasing investment risk. Trading on the OTC Other tier can result from various factors, including financial distress, regulatory non-compliance, or simply a decision by the company not to pursue a higher listing. Compared to NYSE or NASDAQ, the OTC Other tier offers significantly less stringent listing standards and regulatory oversight.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited financial disclosure increases information asymmetry.
- Lower trading volumes can lead to price volatility.
- Wider bid-ask spreads can increase transaction costs.
- Potential for market manipulation due to limited regulatory oversight.
- Higher risk of financial distress or delisting compared to listed exchanges.
- Verify the company's regulatory filings and compliance status.
- Assess the company's financial health and operational performance.
- Evaluate the company's management team and track record.
- Analyze the company's competitive positioning and market opportunities.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Licensed to cultivate and research cannabis.
- Vertically integrated operations.
- Focus on medicinal cannabis.
- Established presence in the Australian market.
Cann Group Limited Aktie: Wichtige Fragen beantwortet
What are the key factors to evaluate for CNGGF?
Cann Group Limited (CNGGF) currently holds an AI score of 39/100, indicating low score. Key strength: Licensed to cultivate and research cannabis.. Primary risk to monitor: Potential: Changes in regulations regarding medicinal cannabis.. This is not financial advice.
How frequently does CNGGF data refresh on this page?
CNGGF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CNGGF's recent stock price performance?
Recent price movement in Cann Group Limited (CNGGF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Licensed to cultivate and research cannabis.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider CNGGF overvalued or undervalued right now?
Determining whether Cann Group Limited (CNGGF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying CNGGF?
Before investing in Cann Group Limited (CNGGF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding CNGGF to a portfolio?
Potential reasons to consider Cann Group Limited (CNGGF) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Licensed to cultivate and research cannabis.. Additionally: Vertically integrated operations.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of CNGGF?
Yes, most major brokerages offer fractional shares of Cann Group Limited (CNGGF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track CNGGF's earnings and financial reports?
Cann Group Limited (CNGGF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for CNGGF earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Limited information available on OTC markets.
- Financial data may be outdated or incomplete.